- Home
- SBLX vs CPHI Comparison
SBLX vs CPHI Comparison
Compare SBLX & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLX
- CPHI
- Stock Information
- Founded
- SBLX 2017
- CPHI N/A
- Country
- SBLX United States
- CPHI China
- Employees
- SBLX N/A
- CPHI N/A
- Industry
- SBLX Telecommunications Equipment
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- SBLX Consumer Discretionary
- CPHI Health Care
- Exchange
- SBLX Nasdaq
- CPHI Nasdaq
- Market Cap
- SBLX 4.0M
- CPHI 4.7M
- IPO Year
- SBLX N/A
- CPHI N/A
- Fundamental
- Price
- SBLX $4.64
- CPHI $1.76
- Analyst Decision
- SBLX
- CPHI
- Analyst Count
- SBLX 0
- CPHI 0
- Target Price
- SBLX N/A
- CPHI N/A
- AVG Volume (30 Days)
- SBLX 609.9K
- CPHI 12.0K
- Earning Date
- SBLX 11-13-2025
- CPHI 11-12-2025
- Dividend Yield
- SBLX N/A
- CPHI N/A
- EPS Growth
- SBLX N/A
- CPHI N/A
- EPS
- SBLX N/A
- CPHI N/A
- Revenue
- SBLX $5,426.00
- CPHI $4,396,201.00
- Revenue This Year
- SBLX N/A
- CPHI N/A
- Revenue Next Year
- SBLX N/A
- CPHI N/A
- P/E Ratio
- SBLX N/A
- CPHI N/A
- Revenue Growth
- SBLX N/A
- CPHI N/A
- 52 Week Low
- SBLX $4.20
- CPHI $1.20
- 52 Week High
- SBLX $15.28
- CPHI $3.35
- Technical
- Relative Strength Index (RSI)
- SBLX 41.56
- CPHI 45.49
- Support Level
- SBLX $4.48
- CPHI $1.64
- Resistance Level
- SBLX $4.99
- CPHI $1.85
- Average True Range (ATR)
- SBLX 0.62
- CPHI 0.08
- MACD
- SBLX -0.08
- CPHI -0.02
- Stochastic Oscillator
- SBLX 6.96
- CPHI 33.33
About SBLX StableX Technologies Inc. Common Stock
StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.